share_log

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

Benzinga ·  May 9 06:56

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment